Intedanib-d3

• CAT Number: R047379
• CAS Number: 1624587-84-3
• Molecular Formula: C31H30D3N5O4
• Molecular Weight: 542.654
• Purity: ≥95%
• Synonyms: (3Z)-2,3-Dihydro-3-[[[4-[methyl[2-(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-H-Indole-6-carboxylic Acid Methyl Ester-d3; BIBF 1120-d3; Ofev-d3; Vargatef-d3; Nintedanib-d3
• Target: PDGFR
• Storage: -20°C
• IUPAC Name: methyl (3Z)-3-[[4-[methyl-[2-[4-(trideuteriomethyl)piperazin-1-yl]acetyl]amino]anilino]-phenylmethylidene]-2-oxo-1H-indole-6-carboxylate
• InChI: InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,32H,15-18,20H2,1-3H3,(H,33,38)/b29-28-/i1D3
• InChIKey: XZXHXSATPCNXJR-LTZCEKDDSA-N
• SMILES: CN1CCN(CC1)CC(=O)N(C)C2=CC=C(C=C2)NC(=C3C4=C(C=C(C=C4)C(=O)OC)NC3=O)C5=CC=CC=C5

Intedanib-d3 is a deuterated form of intedanib, a tyrosine kinase inhibitor used primarily in the treatment of idiopathic pulmonary fibrosis and certain cancers. The incorporation of deuterium atoms enhances its metabolic stability and can improve pharmacokinetic properties. Research on intedanib-d3 focuses on its efficacy, safety, and improved metabolic profile compared to its non-deuterated counterpart. This compound is investigated for its potential to offer better therapeutic outcomes and reduced side effects in clinical settings.